Exploring the role of novel agents in the treatment of renal cell carcinoma. [electronic resource]
Producer: 20081229Description: 750-60 p. digitalISSN:- 1532-1967
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- administration & dosage
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Benzenesulfonates -- adverse effects
- Bevacizumab
- Carcinoma, Renal Cell -- drug therapy
- Chemotherapy, Adjuvant
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Drug Delivery Systems
- Female
- Humans
- Indoles -- adverse effects
- Kidney Neoplasms -- drug therapy
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Metastasis
- Neoplasm Staging
- Nephrectomy -- methods
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Prognosis
- Pyridines -- adverse effects
- Pyrroles -- adverse effects
- Sirolimus -- adverse effects
- Sorafenib
- Sunitinib
- Survival Analysis
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.